Entrada Therapeutics, Inc. (TRDA)
NASDAQ: TRDA · Real-Time Price · USD
6.63
-0.07 (-1.04%)
At close: May 27, 2026, 4:00 PM EDT
6.76
+0.13 (1.96%)
After-hours: May 27, 2026, 6:46 PM EDT
Entrada Therapeutics Employees
Entrada Therapeutics had 152 employees as of December 31, 2025. The number of employees decreased by 31 or -16.94% compared to the previous year.
Employees
152
Change (1Y)
-31
Growth (1Y)
-16.94%
Revenue / Employee
$37,750
Profits / Employee
-$1,092,882
Market Cap
238.90M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 152 | -31 | -16.94% |
| Dec 31, 2024 | 183 | 24 | 15.09% |
| Sep 30, 2024 | 177 | 27 | 18.00% |
| Jun 30, 2024 | 168 | 37 | 28.24% |
| Mar 31, 2024 | 160 | 30 | 23.08% |
| Dec 31, 2023 | 159 | 29 | 22.31% |
| Sep 30, 2023 | 150 | 26 | 20.97% |
| Jun 30, 2023 | 131 | 9 | 7.38% |
| Mar 31, 2023 | 130 | 16 | 14.04% |
| Dec 31, 2022 | 130 | 16 | 14.04% |
| Sep 30, 2022 | 124 | 26 | 26.53% |
| Jun 30, 2022 | 122 | 44 | 56.41% |
| Mar 31, 2022 | 114 | 36 | 46.15% |
| Dec 31, 2021 | 114 | - | - |
| Sep 30, 2021 | 98 | - | - |
| Jun 30, 2021 | 78 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Humacyte | 184 |
| LENZ Therapeutics | 152 |
| Codexis | 146 |
| Adagene | 128 |
| Alector | 103 |
| Orchestra BioMed Holdings | 86 |
| Anavex Life Sciences | 34 |
| Sol-Gel Technologies | 28 |
TRDA News
- 8 days ago - Entrada Therapeutics Transcript: H.C. Wainwright 4th Annual BioConnect Investor Conference - Transcripts
- 16 days ago - Entrada Therapeutics, Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses - GlobeNewsWire
- 18 days ago - Entrada Therapeutics DMD Trial Shows Early Functional Gains, Clean Safety Profile - MarketBeat
- 19 days ago - Entrada Therapeutics price target lowered to $10 from $19 at Roth Capital - TheFly
- 19 days ago - Entrada Therapeutics downgraded to Neutral from Buy at H.C. Wainwright - TheFly
- 20 days ago - Entrada Therapeutics reports topline data from Cohort 1 of ELEVATE-44-201 study - TheFly
- 20 days ago - Entrada Therapeutics reports Q1 EPS (95c), consensus ($1.02) - TheFly
- 20 days ago - Entrada Therapeutics Transcript: Study result - Transcripts